Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.4
5.3
Journals
Nanomaterials
Special Issues
Nanoparticles in Drug Delivery Applications
share announcement

Nanoparticles in Drug Delivery Applications

A special issue of Nanomaterials (ISSN 2079-4991). This special issue belongs to the section "Biology and Medicines".

Deadline for manuscript submissions: 20 August 2024 | Viewed by 3364

Special Issue Editors

Prof. Dr. Barbara Pierscionek

E-Mail Website
Guest Editor
Faculty of Health Education Medicine and Social Care, Anglia Ruskin University, Chelmsford, UK
Interests: vision research; nanomedicine; eye disease, cataracts
Prof. Dr. Mohammad Najlah

E-Mail Website
Guest Editor
Faculty of Health, Education, Medicine & Social Care, Pharmaceutical Research Group, Chelmsford, UK
Interests: dendrimer nanocarriers; biopolymers; clinical pharmaceutics; polymer nanoparticulates
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

There has been growing interest in employing nanotechnology to tackle a wide range of challenges in the field of drug delivery. Nanoparticles have been widely used to enhance drug solubility or/and stability, drug targeting and/or reduce toxicity and side effects. Many nano-based drug delivery systems have found their way to clinics and have been successfully used in the fields of cancer treatment, vaccinations, infectious diseases and ocular diseases. In addition, there have been unprecedented developments in the areas of manufacturing and scaling-up technologies for pharmaceutical nano-formulations. However, there are still numerous challenges in the “nano” research journey from “bench” to “bedside”, such as reproducibility, efficient encapsulation, economic and green scaling-up technologies, safety and biocompatibility.

This Special Issue will shed light on the current advances in using nanoparticles as a drug delivery system with a specific focus on the innovative approaches for nano-fabrications, physical and biological evaluations of the manufactured systems and recent development in scaling-up technologies.  

Prof. Dr. Barbara Pierscionek
Prof. Dr. Mohammad Najlah
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Nanomaterials is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • nanotechnology
  • biological evaluation
  • nano-fabrication
  • cancer treatment
  • vaccinations
  • infectious diseases
  • ocular diseases
  • nanoparticles
  • scaling up

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

13 pages, 3702 KiB  
Article
Hydroxyapatite Nanorods Based Drug Delivery Systems for Bumetanide and Meloxicam, Poorly Water Soluble Active Principles
by Valeria Friuli, Lauretta Maggi, Giovanna Bruni, Francesca Caso and Marcella Bini
Nanomaterials 2024, 14(1), 113; https://0-doi-org.brum.beds.ac.uk/10.3390/nano14010113 - 02 Jan 2024
Viewed by 965
Abstract
Poorly water-soluble drugs represent a challenge for the pharmaceutical industry because it is necessary to find properly tuned and efficient systems for their release. In this framework, organic–inorganic hybrid systems could represent a promising strategy. A largely diffused inorganic host is hydroxyapatite (HAP, [...] Read more.
Poorly water-soluble drugs represent a challenge for the pharmaceutical industry because it is necessary to find properly tuned and efficient systems for their release. In this framework, organic–inorganic hybrid systems could represent a promising strategy. A largely diffused inorganic host is hydroxyapatite (HAP, Ca10(PO4)6(OH)2), which is easily synthesized with different external forms and can adsorb different kinds of molecules, thereby allowing rapid drug release. Hybrid nanocomposites of HAP nanorods, obtained through hydrothermal synthesis, were prepared with two model pharmaceutical molecules characterized by low and pH-dependent solubility: meloxicam, a non-steroidal anti-inflammatory drug, and bumetanide, a diuretic drug. Both hybrids were physically and chemically characterized through the combined use of X-ray powder diffraction, scanning electron microscopy with energy-dispersive spectroscopy, differential scanning calorimetry, and infrared spectroscopy measurements. Then, their dissolution profiles and hydrophilicity (contact angles) in different media as well as their solubility were determined and compared to the pure drugs. This hybrid system seems particularly suitable as a drug carrier for bumetanide, as it shows higher drug loading and good dissolution profiles, while is less suitable for meloxicam, an acid molecule. Full article
(This article belongs to the Special Issue Nanoparticles in Drug Delivery Applications)
►▼ Show Figures

Figure 1

20 pages, 4646 KiB  
Article
Exploring the Potential of siRNA Delivery in Acute Myeloid Leukemia for Therapeutic Silencing
by Anyeld M. Ubeda Gutierrez, K. C. Remant Bahadur, Joseph Brandwein and Hasan Uludağ
Nanomaterials 2023, 13(24), 3167; https://0-doi-org.brum.beds.ac.uk/10.3390/nano13243167 - 18 Dec 2023
Viewed by 923
Abstract
We investigated the feasibility of using siRNA therapy for acute myeloid leukemia (AML) by developing macromolecular carriers that facilitated intracellular delivery of siRNA. The carriers were derived from low-molecular-weight (<2 kDa) polyethyleneimine (PEI) and modified with a range of aliphatic lipids. We identified [...] Read more.
We investigated the feasibility of using siRNA therapy for acute myeloid leukemia (AML) by developing macromolecular carriers that facilitated intracellular delivery of siRNA. The carriers were derived from low-molecular-weight (<2 kDa) polyethyleneimine (PEI) and modified with a range of aliphatic lipids. We identified linoleic acid and lauric acid-modified PEI as optimal carriers for siRNA delivery to AML cell lines KG1 and KG1a, as well as AML patient-derived mononuclear cells. As they have been proven to be potent targets in the treatment of AML, we examined the silencing of BCL2L12 and survivin and showed how it leads to the decrease in proliferation of KG1 and stem-cell-like KG1a cells. By optimizing the transfection schedule, we were able to enhance the effect of the siRNAs on proliferation over a period of 10 days. We additionally showed that with proper modifications of PEI, other genes, including MAP2K3, CDC20, and SOD-1, could be targeted to decrease the proliferation of AML cells. Our studies demonstrated the versatility of siRNA delivery with modified PEI to elicit an effect in leukemic cells that are difficult to transfect, offering an alternative to conventional drugs for more precise and targeted treatment options. Full article
(This article belongs to the Special Issue Nanoparticles in Drug Delivery Applications)
►▼ Show Figures

Figure 1

Review

Jump to: Research

21 pages, 2550 KiB  
Review
An Overview of Polymeric Nanoplatforms to Deliver Veterinary Antimicrobials
by Yaxin Zhou, Lihua Guo, Guonian Dai, Bing Li, Yubin Bai, Weiwei Wang, Shulin Chen and Jiyu Zhang
Nanomaterials 2024, 14(4), 341; https://0-doi-org.brum.beds.ac.uk/10.3390/nano14040341 - 09 Feb 2024
Viewed by 1222
Abstract
There is an urgent need to find new solutions for the global dilemma of increasing antibiotic resistance in humans and animals. Modifying the performance of existing antibiotics using the nanocarrier drug delivery system (DDS) is a good option considering economic costs, labor costs, [...] Read more.
There is an urgent need to find new solutions for the global dilemma of increasing antibiotic resistance in humans and animals. Modifying the performance of existing antibiotics using the nanocarrier drug delivery system (DDS) is a good option considering economic costs, labor costs, and time investment compared to the development of new antibiotics. Numerous studies on nanomedicine carriers that can be used for humans are available in the literature, but relatively few studies have been reported specifically for veterinary pharmaceutical products. Polymer-based nano-DDS are becoming a research hotspot in the pharmaceutical industry owing to their advantages, such as stability and modifiability. This review presents current research progress on polymer-based nanodelivery systems for veterinary antimicrobial drugs, focusing on the role of polymeric materials in enhancing drug performance. The use of polymer-based nanoformulations improves treatment compliance in livestock and companion animals, thereby reducing the workload of managers. Although promising advances have been made, many obstacles remain to be addressed before nanoformulations can be used in a clinical setting. Some crucial issues currently facing this field, including toxicity, quality control, and mass production, are discussed in this review. With the continuous optimization of nanotechnology, polymer-based DDS has shown its potential in reducing antibiotic resistance to veterinary medicines. Full article
(This article belongs to the Special Issue Nanoparticles in Drug Delivery Applications)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop